IonQ (NYSE: IONQ) has announced an investment partnership with the Centre for Commercialization of Regenerative Medicine (CCRM), a leading global accelerator for advanced therapies headquartered in Canada. The collaboration is intended to accelerate next-generation therapeutic development using hybrid quantum and quantum-AI technologies, with IonQ established as the core technology partner across CCRM’s global network of advanced therapy hubs.
The collaboration will initially focus on three technical areas: bioprocess optimization, disease-modeling workflows, and quantum enhanced simulation to support the design and manufacturing of advanced therapies. CCRM, which operates over 100,000 square feet of good manufacturing practice (GMP) facilities and employs over 300 scientific staff, brings therapeutic innovation expertise to the partnership.
The partnership is strategically positioned to generate computational advantages for the life sciences sector. Initial projects are scheduled to launch in Canada and Sweden in 2026, building on IonQ’s existing collaboration with AstraZeneca in Sweden. Michael May, President and CEO of CCRM, noted that the collaboration will help accelerate the discovery and application of advanced therapies by unlocking solutions previously beyond reach.
Read the full announcement here.
In GQI Portal
The players behind the news
The team that writes QCR tracks every company, deal and technology in the GQI Factory, GQI's verified database of the quantum industry. Next up: every story linked to its players, coming to QCR's paid plans.
- Players Companies and institutions across the quantum industry, by segment.
- Scorecards How the players compare on hardware, software, funding and more.
Newsletter
QCR Alerts in your inbox
The latest reporting and analysis from Quantum Computing Report. Free, unsubscribe any time.